ESSA Pharma Competitors and Similar CompaniesClear all
ESSA Pharma's competitors and similar companies include MEI Pharma, Candel Therapeutics, Urogen Pharma, AZTherapies and Astria Therapeutics.
 ESSA Pharma ESSA Pharma is a pharmaceutical company focused on developing therapies for the treatment of prostate cancer. |  MEI Pharma MEI Pharma is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. |  Candel Therapeutics Candel Therapeutics (formerly known as Advantagene) is a biopharmaceutical company developing cancer immunotherapies. |  AZTherapies AZTherapies is a developer of pharmaceutical drugs designed to provide treatment for multiple neurodegenerations and neuroinflammation-related CNS diseases. |  Astria Therapeutics Astria Therapeutics (formerly known as Catabasis Pharmaceuticals) discovers and develops innovative drugs for treating inflammatory conditions. | ||
Founding Date | Founding Date 2009 | Founding Date 2000 | Founding Date 1999 | Founding Date 2004 | Founding Date 2011 | Founding Date 2008 |
Type | Type Public | Type Public | Type Public | Type Public | Type Private | Type Public |
Tags | ||||||
Locations | Locations Vancouver, CA HQ Houston, US South San Francisco, US | Locations San Diego, US HQ | Locations Needham, US HQ | Locations New York, US HQ Tel Aviv Yafo, IL Princeton, US | Locations Boston, US HQ | Locations Boston, US HQ |
Employees | Employees 50 | Employees 4025% increase | Employees 50 | Employees 194362% increase | Employees 10 | Employees 2433% decrease |
Valuation ($) | Valuation ($) 257.8 m | Valuation ($) 19.1 m | Valuation ($) 222.3 m | Valuation ($) 534.8 m | Valuation ($) N/A | Valuation ($) 655.7 m |
Financial | ||||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $65.3m (FY, 2024) | Revenue (est.) N/A | Revenue (est.) $82.7m (FY, 2023) | Revenue (est.) N/A | Revenue (est.) N/A |
Net income | Net income ($26.6m) (FY, 2023) | Net income $17.8m (FY, 2024) | Net income ($37.9m) (FY, 2023) | Net income ($102.2m) (FY, 2023) | Net income N/A | Net income ($72.9m) (FY, 2023) |
Funding | ||||||
Total funding raised | Total funding raised $ 74.1m | Total funding raised $ 1.1m | Total funding raised $ 64.6m | Total funding raised N/A | Total funding raised $ 97.7m | Total funding raised $ 94.9m |
For sources of this data, please see the company profile
View Company Profiles
MEI Pharma
HQ
San Diego, US
Employees
40↑ 25% increase
MEI Pharma is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer.
View companyCandel Therapeutics
HQ
Needham, US
Employees
50
Candel Therapeutics (formerly known as Advantagene) is a biopharmaceutical company developing cancer immunotherapies.
View company
Urogen Pharma
HQ
New York, US
Employees
194
UroGen Pharma is a clinical-stage biopharmaceutical company.
View companyAZTherapies
HQ
Boston, US
Employees
10
AZTherapies is a developer of pharmaceutical drugs designed to provide treatment for multiple neurodegenerations and neuroinflammation-related CNS diseases.
View company